Technical Articles

KRAS G12D mutation
KRAS G12D抑制剂耐药机制与联合治疗策略研究进展
Research Progress on Resistance Mechanisms and Combination Therapy Strategies of KRAS G12D Inhibitors
发布时间 2026-03-05
The KRAS G12D mutation is one of the most common driver mutations in malignant tumors such as pancreatic cancer and colorectal cancer, with a significantly higher incidence than the KRAS G12C mutation.
View details
  • Cancer
  • KRAS G12D mutation
  • Pancreatic cancer
  • Colorectal cancer
Total 1
  • 1
Go to
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.